570 related articles for article (PubMed ID: 25984993)
21. DNA vaccines for cancer.
Boyd D; Hung CF; Wu TC
IDrugs; 2003 Dec; 6(12):1155-64. PubMed ID: 14666426
[TBL] [Abstract][Full Text] [Related]
22. DNA vaccination against tumors.
Prud'homme GJ
J Gene Med; 2005 Jan; 7(1):3-17. PubMed ID: 15538731
[TBL] [Abstract][Full Text] [Related]
23. A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity.
Walters JN; Ferraro B; Duperret EK; Kraynyak KA; Chu J; Saint-Fleur A; Yan J; Levitsky H; Khan AS; Sardesai NY; Weiner DB
Mol Ther; 2017 Apr; 25(4):976-988. PubMed ID: 28237837
[TBL] [Abstract][Full Text] [Related]
24. The site of administration influences both the type and the magnitude of the immune response induced by DNA vaccine electroporation.
Vandermeulen G; Vanvarenberg K; De Beuckelaer A; De Koker S; Lambricht L; Uyttenhove C; Reschner A; Vanderplasschen A; Grooten J; Préat V
Vaccine; 2015 Jun; 33(28):3179-85. PubMed ID: 25980430
[TBL] [Abstract][Full Text] [Related]
25. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.
Moeini S; Saeidi M; Fotouhi F; Mondanizadeh M; Shirian S; Mohebi A; Gorji A; Ghaemi A
Arch Virol; 2017 Feb; 162(2):333-346. PubMed ID: 27699512
[TBL] [Abstract][Full Text] [Related]
26. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
27. Tapping the Potential of DNA Delivery with Electroporation for Cancer Immunotherapy.
Kraynyak KA; Bodles-Brakhop A; Bagarazzi M
Curr Top Microbiol Immunol; 2017; 405():55-78. PubMed ID: 25682101
[TBL] [Abstract][Full Text] [Related]
28. DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time.
Chudley L; McCann K; Mander A; Tjelle T; Campos-Perez J; Godeseth R; Creak A; Dobbyn J; Johnson B; Bass P; Heath C; Kerr P; Mathiesen I; Dearnaley D; Stevenson F; Ottensmeier C
Cancer Immunol Immunother; 2012 Nov; 61(11):2161-70. PubMed ID: 22729556
[TBL] [Abstract][Full Text] [Related]
29. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
30. PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization.
Rekoske BT; Smith HA; Olson BM; Maricque BB; McNeel DG
Cancer Immunol Res; 2015 Aug; 3(8):946-55. PubMed ID: 26041735
[TBL] [Abstract][Full Text] [Related]
31. DNA fusion vaccines induce epitope-specific cytotoxic CD8(+) T cells against human leukemia-associated minor histocompatibility antigens.
Rice J; Dunn S; Piper K; Buchan SL; Moss PA; Stevenson FK
Cancer Res; 2006 May; 66(10):5436-42. PubMed ID: 16707472
[TBL] [Abstract][Full Text] [Related]
32. MC32 tumor cells acquire Ag-specific CTL resistance through the loss of CEA in a colon cancer model.
Lee SY; Sin JI
Hum Vaccin Immunother; 2015; 11(8):2012-20. PubMed ID: 25902414
[TBL] [Abstract][Full Text] [Related]
33. Electroporation for DNA immunization: clinical application.
van Drunen Littel-van den Hurk S; Hannaman D
Expert Rev Vaccines; 2010 May; 9(5):503-17. PubMed ID: 20450325
[TBL] [Abstract][Full Text] [Related]
34. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells.
Johnson LE; Frye TP; Chinnasamy N; Chinnasamy D; McNeel DG
Cancer Immunol Immunother; 2007 Jun; 56(6):885-95. PubMed ID: 17102977
[TBL] [Abstract][Full Text] [Related]
35. The potential of DNA vaccination against tumor-associated antigens for antitumor therapy.
Haupt K; Roggendorf M; Mann K
Exp Biol Med (Maywood); 2002 Apr; 227(4):227-37. PubMed ID: 11910045
[TBL] [Abstract][Full Text] [Related]
36. Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines.
Hauser H; Shen L; Gu QL; Krueger S; Chen SY
Gene Ther; 2004 Jun; 11(11):924-32. PubMed ID: 15085173
[TBL] [Abstract][Full Text] [Related]
37. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
38. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
39. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems.
Gregor PD; Wolchok JD; Ferrone CR; Buchinshky H; Guevara-Patiño JA; Perales MA; Mortazavi F; Bacich D; Heston W; Latouche JB; Sadelain M; Allison JP; Scher HI; Houghton AN
Vaccine; 2004 Apr; 22(13-14):1700-8. PubMed ID: 15068853
[TBL] [Abstract][Full Text] [Related]
40. Enhanced antitumor effect against human telomerase reverse transcriptase (hTERT) by vaccination with chemotactic-hTERT gene-modified tumor cell and the combination with anti-4-1BB monoclonal antibodies.
Lin X; Zhou C; Wang S; Wang D; Ma W; Liang X; Lin C; Wang Z; Li J; Guo S; Zhang Y; Zhang S
Int J Cancer; 2006 Oct; 119(8):1886-96. PubMed ID: 16708388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]